SANGAMO THERAPEUTICS, INC - FORM 10-K - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - February 16, 2011

Attached files

file filename
10-K - FORM 10-K - SANGAMO THERAPEUTICS, INCd10k.htm
EX-31.2 - RULE 13A-14(A) CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - SANGAMO THERAPEUTICS, INCdex312.htm
EX-31.1 - RULE 13A-14(A) CERTIFICATION OF CHIEF EXECUTIVE OFFICER - SANGAMO THERAPEUTICS, INCdex311.htm
EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 - SANGAMO THERAPEUTICS, INCdex321.htm
EX-10.50 - LETTER AGREEMENT AMENDMENT REGARDING THE RESEARCH AND COMMERCIAL LICENSE OPTION - SANGAMO THERAPEUTICS, INCdex1050.htm
EX-10.49 - SEVENTH AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENT - SANGAMO THERAPEUTICS, INCdex1049.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-166220, 333-157733, 333-34196, 333-64642 and 333-132823) and in the Registration Statement (Form S-3 No. 333-157732) and in the related prospectuses of Sangamo BioSciences, Inc. of our reports dated February 16, 2011, with respect to the consolidated financial statements of Sangamo BioSciences, Inc., and the effectiveness of internal control over financial reporting of Sangamo BioSciences, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2010.

/s/ ERNST & YOUNG LLP

Palo Alto, California

February 16, 2011

Stock widget

Investing forum

SANGAMO THERAPEUTICS, INC Reports